Related references
Note: Only part of the references are listed.Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans
Deborah W. Knapp et al.
FRONTIERS IN ONCOLOGY (2020)
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jeremy Beguin et al.
BMC VETERINARY RESEARCH (2020)
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jeremy Beguin et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M. Moehler et al.
ONCOIMMUNOLOGY (2019)
Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview
G. Romano et al.
DRUGS OF TODAY (2019)
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
Michael P. O'Leary et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
Valerio Leoni et al.
PLOS PATHOGENS (2018)
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
Riikka Havunen et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors
Frederique Nguyen et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance
Jerome Abadie et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Oncolytic Viruses in Cancer Treatment A Review
Sean E. Lawler et al.
JAMA ONCOLOGY (2017)
Immune System, Friend or Foe of Oncolytic Virotherapy?
Anna C. Finley et al.
FRONTIERS IN ONCOLOGY (2017)
Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma
Loren K. Mell et al.
CLINICAL CANCER RESEARCH (2017)
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend et al.
CANCER RESEARCH (2017)
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
Laetitia Fend et al.
ONCOIMMUNOLOGY (2016)
Oncolytic viruses: finally delivering
Leonard W. Seymour et al.
BRITISH JOURNAL OF CANCER (2016)
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Stephanie Downs-Canner et al.
MOLECULAR THERAPY (2016)
Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
Rachel Myers et al.
MOLECULAR THERAPY (2016)
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1
[Anonymous]
VETERINARY AND COMPARATIVE ONCOLOGY (2016)
Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma
Che-Hsuan Kung et al.
BMC CANCER (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park et al.
MOLECULAR THERAPY (2015)
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques
Laura Evgin et al.
MOLECULAR THERAPY (2015)
Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients
Timothy P. Cripe et al.
MOLECULAR THERAPY (2015)
First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity
Herbert J. Zeh et al.
MOLECULAR THERAPY (2015)
Significance of ERα, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor
Hitomi Shinoda et al.
JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION (2014)
Development and comparison of a quantitative TaqMan-MGB real-time PCR assay to three other methods of quantifying vaccinia virions
Jonathon L. Baker et al.
JOURNAL OF VIROLOGICAL METHODS (2014)
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
Karoliina Autio et al.
MOLECULAR THERAPY-ONCOLYTICS (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity
Geoffrey L. Smith et al.
JOURNAL OF GENERAL VIROLOGY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Canine tumors: a spontaneous animal model of human carcinogenesis
Salome S. Pinho et al.
TRANSLATIONAL RESEARCH (2012)
Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles
Mark S. Ferguson et al.
ADVANCES IN VIROLOGY (2012)
Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging
A. Biondo et al.
EUROPEAN JOURNAL OF CANCER (2011)
OTS Highlights Advance in Basic and Translational Aspects of Oligonucleotide Research
John J. Rossi
MOLECULAR THERAPY (2011)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses
Naomi De Silva et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Methods and mortality results of a health survey of purebred dogs in the UK
V. J. Adams et al.
JOURNAL OF SMALL ANIMAL PRACTICE (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Long-lasting stability of Vaccinia virus strains in murine feces: implications for virus circulation and environmental maintenance
Jonatas S. Abrahao et al.
ARCHIVES OF VIROLOGY (2009)
Comparative expression pathway analysis of human and canine mammary tumors
Paolo Uva et al.
BMC GENOMICS (2009)
Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: An investigation of potential fomites in the home environment
Edith Lederman et al.
VACCINE (2009)
Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus
J. Foloppe et al.
GENE THERAPY (2008)
Cancer incidence in pet dogs: Findings of the animal tumor registry of Genoa, Italy
D. F. Merlo et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate
Kenneth N. Barton et al.
MOLECULAR THERAPY (2008)
Science and society - Translation of new cancer treatments from pet dogs to humans
Melissa Paoloni et al.
NATURE REVIEWS CANCER (2008)
Modified vaccinia virus Ankara as a vector for suicide gene therapy
P. Erbs et al.
CANCER GENE THERAPY (2008)
Detection of vaccinia virus DNA, but not infectious virus, in the blood of smallpox vaccine recipients
Jeffrey I. Cohen et al.
VACCINE (2007)
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Ta-Chiang Liu et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Long-lasting stability of vaccinia virus (orthopoxvirus) in food and environmental samples
S. Essbauer et al.
ZOONOSES AND PUBLIC HEALTH (2007)
Of humans and canines:: Immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours
R. Kumaraguruparan et al.
RESEARCH IN VETERINARY SCIENCE (2006)
Cytolytic viruses as potential anti-cancer agents
CJA Ring
JOURNAL OF GENERAL VIROLOGY (2002)
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
D Kirn et al.
NATURE MEDICINE (2001)
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
NJ Tao et al.
MOLECULAR THERAPY (2001)
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer
T Hermiston
JOURNAL OF CLINICAL INVESTIGATION (2000)
Spontaneously occurring tumors of companion animals as models for human cancer
DM Vail et al.
CANCER INVESTIGATION (2000)
Share Paper
